458
person
Gonzalo Luchetti
person
Taimur Hyat
person
Daphne Kis
staff
Hilary McConnaughey Page
Hilary McConnaughey Page, an associate director, has spent nearly a decade of her career in phila
nthropy, advising foundations, corporations, and high-net-worth individuals on their charitable endeavors.
+ Read More
staff
Erin Ross
Erin Ross is a Director of MI Philanthropy working on the Center for Strategic Philanthropy’s bio
medical portfolio.
+ Read More
staff
Julie Monaco
staff
James R. Barth
report
Alzheimer's Disease - A Giving Smarter Guide
Alzheimer’s disease is increasingly in the spotlight after a number of high-profile clinical trial
failures—an alarming trend as an estimated 5.5 million adult Americans live with this disease, which disproportionally affects the aged population.
+ Read More
report
The Rise of FinTech in the Middle East: An Analysis of the Emergence of Bahrain and the United Arab Emirates
FinTech regulatory regimes started emerging in the Gulf region in 2017.
report
Private Equity IPOs: Generating Faster Job Growth and More Investment
Private-equity firms have become an increasingly important source of funds for financing US compani
es. Private-equity firms make investment decisions that can brighten or darken the economic outlook of the communities in which their companies operate.
+ Read More
report
Financing Urban Resiliency: Coastal Resiliency in Lower Manhattan
Cities across the US, particularly those along the coasts, are facing mounting threats from climate
change and sea-level rise. In New York City, Lower Manhattan was hit particularly hard by Hurricane Sandy in 2012.
+ Read More
report
Targeting Tau — Our Hope to Solving the Dementia Crisis
In our systems-based review of the biomedical landscape supporting research of a cellular protein c
alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions
At present, no disease-modifying therapies for the pure tauopathies exist.
+ Read More